Last $3.22 USD
Change Today -0.105 / -3.16%
Volume 1.2M
IDRA On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 12:26 PM 04/23/14 All times are local (Market data is delayed by at least 15 minutes).

idera pharmaceuticals inc (IDRA) Snapshot

Open
$3.21
Previous Close
$3.32
Day High
$3.31
Day Low
$3.13
52 Week High
03/18/14 - $6.87
52 Week Low
05/2/13 - $0.52
Market Cap
264.8M
Average Volume 10 Days
2.9M
EPS TTM
$-0.46
Shares Outstanding
82.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for IDERA PHARMACEUTICALS INC (IDRA)

Related News

No related news articles were found.

idera pharmaceuticals inc (IDRA) Related Businessweek News

No Related Businessweek News Found

idera pharmaceuticals inc (IDRA) Details

Idera Pharmaceuticals, Inc., a clinical stage biotechnology company, is engaged in the discovery and development of novel therapeutics that modulate immune responses through toll-like receptors (TLRs) in the United States. The company’s lead drug candidates in TLR program includes IMO-8400, which is in Phase 1/2 clinical trials for the treatment of various autoimmune diseases, such as moderate to severe plaque psoriasis, polymyositis, dermatomyositis, Waldenström’s macroglobulinemia, and diffuse large B-cell lymphoma; and IMO-9200 that is in preclinical studies that supports the submission of an investigational new drug application to the United States Food and Drug Administration. It is also involved in the initiation of research program that employs gene silencing oligonucleotides to inhibit the production of disease-associated proteins by targeting RNA. The company has license agreement with Merck KGaA to research, develop, and commercialize products containing its TLR9 agonists for the treatment of cancer; and license and research collaboration agreement with Merck Sharp & Dohme Corp. to develop and commercialize TLR7, TLR8, and TLR9 agonists in the fields of cancer, infectious diseases, and Alzheimer’s disease. Idera Pharmaceuticals, Inc. was founded in 1989 and is based in Cambridge, Massachusetts.

18 Employees
Last Reported Date: 03/13/14
Founded in 1989

idera pharmaceuticals inc (IDRA) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $549.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $315.0K
Vice President of Clinical Development
Total Annual Compensation: $300.0K
Vice President of Development Programs & Alli...
Total Annual Compensation: $299.0K
Compensation as of Fiscal Year 2012.

idera pharmaceuticals inc (IDRA) Key Developments

Idera Launches User Community Site

Idera announced the launch of its new community site, a virtual gathering place for users of Idera, CopperEgg and Precise technologies. The new community, accessible at community.idera.com, offers Idera's nearly 330,000 users a place to collaborate and share information as well as join ongoing product forum discussions. Community members can solicit advice from fellow users and Idera experts, including product managers, architects and engineers, as well as vote on new products and feature enhancements. The site will help users optimize usage of Idera, CopperEgg, and Precise products by offering industry-targeted blog posts, insider tips and deep-dive tool explorations.

Idera Pharmaceuticals, Inc. Announces Preclinical Data from B-Cell Lymphoma Study

Idera Pharmaceuticals, Inc. has announced new preclinical data demonstrating the ability of its Toll-like receptor, or TLR, antagonist, IMO-8400, to inhibit the survival and proliferation of B-cell lymphoma cells harboring the oncogenic MYD88 L265P genetic mutation. The data presented at AACR build upon reports from several independent investigators and provide additional evidence that the MYD88 L265P mutation, which is present in certain B-cell lymphomas, results in over-activation of TLR7 and TLR9 mediated signaling. Blocking these TLRs leads to tumor cell death. IMO-8400, a first-in-class synthetic oligonucleotide-based antagonist of TLRs 7, 8, and 9, is in clinical development for the treatment of patients with Waldenström's macroglobulinemia and patients with diffuse large B-cell lymphoma (DLBCL) who harbor the MYD88 L265P mutation. In the presentation, entitled 'IMO-8400, a selective antagonist of TLRs 7, 8 and 9, inhibits MYD88 L265P mutation-driven signaling and cell survival: A potential novel approach for treatment of B-cell lymphomas harboring MYD88 L265P mutation,' Idera observed that the knockdown of TLR7 and TLR9 expression in DLBCL cells with the MYD88 L265P mutation led to decreased cell signaling, and inhibition of cell survival, consistent with previous reports of other investigators. In the experiments presented, treatment of DLBCL cells expressing the MYD88 L265P mutation with IMO-8400 led to cell death and decreased proliferative cell signaling. Key signaling pathways inhibited include IRAK-1, IRAK-4, BTK, STAT-3, I?-Ba, and NF?-B. Treatment with IMO-8400 also inhibited growth of established tumors of human DLBCL cells harboring the MYD88 L265P mutation in a mouse model. In addition, treatment with IMO-8400 of Waldenström's macroglobulinemia cells expressing the MYD88 L265P mutation led to similar negative effects on cell signaling and survival. The company anticipates that patient treatment in this trial will begin in the second quarter of 2014. Idera has also submitted a separate protocol to the FDA to conduct a Phase I/II trial in patients with DLBCL who harbor the MYD88 L265P mutation. Idera's TLR antagonist drug candidates have been created using a proprietary chemistry-based drug discovery platform. IMO-8400 is a first-in-class synthetic oligonucleotide-based antagonist of TLRs 7, 8, and 9. IMO-8400 has shown activity in preclinical models of autoimmune diseases, including psoriasis, lupus, and arthritis. IMO-8400 has been well-tolerated in a Phase I trial in 42 healthy subjects at single and multiple escalating doses up to 0.6 mg/kg for four weeks, and has shown inhibition of immune responses mediated by TLRs 7, 8, and 9. In addition, recently announced top-line data from a Phase II trial demonstrated that IMO-8400 was well-tolerated and showed evidence of clinical activity in patients with psoriasis who were treated at doses of up to 0.3 mg/kg/week for 12 weeks.

Idera Pharmaceuticals Announces Positive Top-line Data in Phase 2 Trial of IMO-8400

Idera Pharmaceuticals, Inc. announced positive top-line data from its randomized, double-blind, placebo controlled Phase 2 trial of IMO-8400 in 32 patients with moderate-to-severe plaque psoriasis. The primary objective of the trial was to evaluate the safety and tolerability of IMO-8400 over a 12-week treatment period, with a secondary objective to evaluate the clinical activity of IMO-8400. The trial met its primary objective as all treatments were well tolerated with no treatment related discontinuation, serious adverse events or dose reductions. IMO-8400 treatment met the secondary objective of demonstrating clinical activity in patients with psoriasis, as assessed by Psoriasis Area and Severity Index (PASI). IMO-8400, which is Idera's lead clinical candidate, is an antagonist of Toll-like receptors (TLRs) 7, 8, and 9. Idera's strategy is to develop IMO-8400 for the treatment of genetically defined forms of B-cell lymphoma and orphan autoimmune diseases. The trial met its primary objective of demonstrating safety and tolerability at all three dose levels. For all subjects, treatment was well tolerated with no treatment related discontinuation, serious adverse events or dose reductions. The trial also met a secondary objective of demonstrating clinical activity based on PASI scores. Among patients who completed 12 weeks of treatment per protocol, PASI 50 was achieved in nine (45%) of 20 who received IMO-8400 at any dose level, and in one (14%) of seven who received placebo. PASI 75 was achieved in four (20%) of IMO-8400 treated patients at any dose level, and in zero placebo patients. PASI 50 and PASI 75 are defined as 50% and 75% improvement, respectively, compared to baseline PASI. This Phase 2 trial is a randomized, double-blind, placebo-controlled trial, in which the Company enrolled 32 patients with moderate-to-severe plaque psoriasis, with a minimum PASI score of 12 or above. All patients were withdrawn from prior therapies with an appropriate wash-out period, and were randomized equally to receive subcutaneous IMO-8400 monotherapy at dose levels of 0.075 mg/kg, 0.15 mg/kg and 0.3 mg/kg or placebo, weekly for 12 weeks, with a six-week follow-up period. The primary objective of the trial was to evaluate the safety and tolerability of IMO-8400. A secondary objective of the trial was to evaluate the clinical activity of IMO-8400 as assessed using standard clinical metrics, including Psoriasis Area and Severity Index (PASI) scores.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IDRA:US $3.21 USD -0.11

IDRA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IDRA.
View Industry Companies
 

Industry Analysis

IDRA

Industry Average

Valuation IDRA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4,506.4x
Price/Book 10.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 4,958.3x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IDERA PHARMACEUTICALS INC, please visit www.iderapharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.